ConductScience.org, home

Library / Trial comparisons

E-MOTIVE Intervention vs Usual Care: Number of Women Receiving Any Treatment Uterotonic for PPH

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.9980.9960.999wilsonClinicalTrials.gov
Risk in group 20.9270.9190.934wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.0710.06390.0787newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.081.071.09logClinicalTrials.gov
Odds ratio, group 1 over group 238.821.869.1logClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on E-MOTIVE Intervention than on Usual Care14.112.715.6from the risk difference intervalClinicalTrials.gov

Groups 2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1E-MOTIVE Intervention
The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case.
5,9095,921OG000ClinicalTrials.gov
Group 2Usual CareUsual care with dissemination of the current guidelines~Usual care: Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.4,5414,899OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Women Receiving Any Treatment Uterotonic for PPHClinicalTrials.gov
DescriptionClinicalTrials.gov
Time frameUp to 24 hours postpartumClinicalTrials.gov
PopulationNumber of womenClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given BirthClinicalTrials.gov
NCT numberNCT04341662ClinicalTrials.gov
PhasesNAClinicalTrials.gov
ConditionsPost-Partum HaemorrhageClinicalTrials.gov
InterventionsE-MOTIVE intervention, Usual careClinicalTrials.gov
Lead sponsorUniversity of BirminghamClinicalTrials.gov
Results first posted2024-08-06ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT04341662?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.